Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 12/20 | 1.00 |
| ▸ | PARP1 | P09874 | 10/20 | 1.00 |
| ▸ | PARP11 | Q9NR21 | 8/20 | 1.00 |
| ▸ | PDPK1 | O15530 | 1/20 | 1.00 |
| ▸ | CA12 | O43570 | 1/20 | 0.63 |
| ▸ | CA9 | Q16790 | 1/20 | 0.63 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.58 |
| ▸ | TUBB | P07437 | 1/20 | 0.58 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.58 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.58 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.58 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.58 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.58 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.58 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.58 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.58 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.58 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.58 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.58 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL67710 | 1.00 | PARP10 (1.00) | PARP10PARP1PARP11PDPK1CA12 | |
| Hydrochloric Acid SCHEMBL29896921 | 0.98 | PARP10 (0.96) | PARP10PARP1PARP11PDPK1CA12 | |
| Hydrochloric Acid SCHEMBL10647408 | 0.98 | PARP10 (0.96) | PARP10PARP1PARP11PDPK1CA12 | |
| Piperazine SCHEMBL28321362 | 0.94 | PARP10 (0.89) | PARP10PARP1PARP11PDPK1CA12 | |
| SCHEMBL1894080 | 0.88 | PARP10 (0.78) | PARP10PARP1PARP11PDPK1CA12 | |
| SCHEMBL20076060 | 0.86 | PARP10 (0.75) | PARP10PARP1PARP11PDPK1CA12 | |
| SCHEMBL29752161 | 0.86 | PARP10 (0.75) | PARP10PARP1PARP11PDPK1CA12 | |
| Trifluoroacetic Acid SCHEMBL28415123 | 0.85 | PARP10 (0.72) | PARP10PARP1PARP11PDPK1CA12 | |
| SCHEMBL28691391 | 0.82 | PARP1 (0.68) | PARP10PARP1PARP11PDPK1CA12 | |
| SCHEMBL30114663 | 0.81 | PARP10 (0.67) | PARP10PARP1PARP11PDPK1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 205 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3768675-B1 | NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORP (KR) | 2026-04-01 | — | — | EP | claimed |
| US-20250178999-A1 | ONE STEP SYNTHESIS OF 1-TETRALONE COMPOUNDS AND USES THEREOF IN THE PREPARATION OF (+)-TETRALONE ABSCISIC ACID (ABA) | UNIVERSITY OF SASKATCHEWAN (CA) | 2025-06-05 | — | — | US | claimed |
| CN-119823040-A | Preparation method of amido-containing 3, 4-dihydro-isoquinoline-1 (2H) -ketone derivative | 浙江理工大学嵊州创新研究院有限公司 | 2025-04-15 | — | — | CN | claimed |
| EP-4514784-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | Petra Pharma Corporation (US) | 2025-03-05 | — | — | EP | claimed |
| CN-119506909-A | Method for electrochemically synthesizing 3, 4-dihydro-isoquinoline-1 (2H) -ketone compound | 宜宾学院 | 2025-02-25 | — | — | CN | claimed |
| CN-119301106-A | Allosteric benzopyrone inhibitors of phosphoinositide 3-kinase (PI 3K) for the treatment of disease | 佩特拉制药公司 | 2025-01-10 | — | — | CN | claimed |
| EP-4050006-B1 | BICYCLIC COMPOUND AND USE THEREOF | SK BIOPHARMACEUTICALS CO LTD (KR) | 2025-01-01 | — | — | EP | claimed |
| CN-118894816-A | 3, 3-Difluoroallylamine or salt thereof and pharmaceutical composition comprising the same | 柳韩洋行 | 2024-11-05 | — | — | CN | claimed |
| CN-118791431-A | Dihydro-isoquinolone compounds and isoindoles Selective synthesis method of pinone compound | 常州大学 | 2024-10-18 | — | — | CN | claimed |
| EP-4415818-A1 | 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AS DYRK1A INHIBITORS | BioSplice Therapeutics, Inc. (US) | 2024-08-21 | — | — | EP | claimed |
| CN-113330001-B | 3, 3-Difluoroallylamine or salt thereof and pharmaceutical composition comprising the same | 柳韩洋行 | 2024-07-02 | — | — | CN | claimed |
| EP-3386511-B2 | METHODS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS INC (US) | 2024-03-20 | — | — | EP | claimed |
| CN-115515947-B | SHP2 inhibitor, composition and application thereof | 贝达药业股份有限公司 | 2024-02-06 | — | — | CN | claimed |
| CN-111886233-B | Triazolone derivatives or salts thereof and pharmaceutical compositions containing the same | 柳韩洋行 | 2024-01-02 | — | — | CN | claimed |
| WO-2023212693-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PETRA PHARMA CORPORATION (US) | 2023-11-02 | — | — | WO | claimed |
| WO-2023064361-A1 | 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AS DYRK1A INHIBITORS | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-04-20 | — | — | WO | claimed |
| CN-111825656-B | Inhibitors of protein arginine methyltransferase 5 (PRMT 5), pharmaceutical products thereof, and methods thereof | 南京药石科技股份有限公司 | 2023-03-31 | — | — | CN | claimed |
| CN-115515947-A | SHP2 inhibitor and composition and application thereof | 贝达药业股份有限公司 | 2022-12-23 | — | — | CN | claimed |
| CN-115093369-A | Synthetic method of 3, 4-dihydroisoquinoline-1-ketone compound | 浙大城市学院 | 2022-09-23 | — | — | CN | claimed |
| EP-4747250-A1 | KINASE INHIBITORS | The United States Of America, As Represented By The Secretary, Department of Health and Human Services (US) | 2026-05-27 | — | — | EP | disclosed |
| CN-122094935-A | Amide prodrugs and uses thereof | — | 2026-05-26 | — | — | CN | disclosed |
| US-12637461-B2 | Compounds for the activation of AMPK | PFIZER INC. (US) | 2026-05-26 | — | — | US | disclosed |
| CN-115835909-B | Cannabinoid receptor type 2 (CB 2) modulators and uses thereof | 泰昂治疗公司 | 2026-05-15 | — | — | CN | disclosed |
| US-20260132132-A1 | 3A,4,5,6-TETRAHYDRO-1 H-PYRAZOLO[3,4-C]PYRIDIN-7(7AH)-ONE DERIVATIVES AS FACTOR XIIA INHIBITORS | KALVISTA PHARMACEUTICALS LTD (GB) | 2026-05-14 | — | — | US | disclosed |
| CN-116583303-B | Tripterine conjugates and uses thereof | 瑞阳公司 | 2026-05-12 | — | — | CN | disclosed |
| EP-4694931-A1 | EXTRAHEPATIC DELIVERY OF DOUBLE-STRANDED RNA AGENTS | Alnylam Pharmaceuticals, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-4448513-A4 | 3, 4-DIHYDROISOQUINOLIN-1 (2H) -ONES DERIVATIVES AS STING ANTAGONISTS AND THE USE THEREOF | BEIGENE SWITZERLAND GMBH (CH) | 2025-11-05 | — | — | EP | disclosed |
| US-20250320184-A1 | SARM1 MODULATORS, PREPARATIONS, AND USES THEREOF | SIRONAX LTD (KY) | 2025-10-16 | — | — | US | disclosed |
| US-12391674-B2 | Heterocyclic compounds for the treatment of epilepsy | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2025-08-19 | — | — | US | disclosed |
| US-12331035-B2 | Bicyclic compound and use thereof | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2025-06-17 | — | — | US | disclosed |
| CN-120152713-A | Tricyclic aryl derivatives and compositions and methods thereof | 昂胜医疗科技公司 | 2025-06-13 | — | — | CN | disclosed |
| US-20250178999-A1 | ONE STEP SYNTHESIS OF 1-TETRALONE COMPOUNDS AND USES THEREOF IN THE PREPARATION OF (+)-TETRALONE ABSCISIC ACID (ABA) | UNIVERSITY OF SASKATCHEWAN (CA) | 2025-06-05 | — | — | US | disclosed |
| CN-120051461-A | VHH antibody conjugates | 雅博得乐医疗公司 | 2025-05-27 | — | — | CN | disclosed |
| CN-120025312-A | Benzazepine derivatives | 大塚制药株式会社 | 2025-05-23 | — | — | CN | disclosed |
| CN-114516856-B | Dihydro-isoquinolinone and isoindolinone derivatives and application thereof | 安徽中科拓苒药物科学研究有限公司 | 2025-05-23 | — | — | CN | disclosed |
| CN-114516856-B | Dihydro-isoquinolinone and isoindolinone derivatives and application thereof | 安徽中科拓苒药物科学研究有限公司 | 2025-05-23 | — | — | CN | disclosed |
| US-20250161247-A1 | METHOD FOR TREATING BREAST CANCERS AND PARP RESISTANT BREAST CANCERS | LANTERN PHARMA INC. (US) | 2025-05-22 | — | — | US | disclosed |
| EP-4554683-A2 | METHOD FOR TREATING BREAST CANCERS AND PARP RESISTANT BREAST CANCERS | Lantern Pharma Inc. (US) | 2025-05-21 | — | — | EP | disclosed |
| CN-119930578-A | Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith | 细胞基因公司 | 2025-05-06 | — | — | CN | disclosed |
| CN-119907795-A | Antibacterial compounds | 布莱克史密斯医药公司 | 2025-04-29 | — | — | CN | disclosed |
| EP-4536350-A1 | SUBSTITUTED 3,4-DIHYDROISOQUINOLIN-1(2H)-ONE DERIVATIVES AND RELATED USES | Nodthera Limited (GB) | 2025-04-16 | — | — | EP | disclosed |
| EP-4536640-A1 | SARM1 MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2025-04-16 | — | — | EP | disclosed |
| CN-119823040-A | Preparation method of amido-containing 3, 4-dihydro-isoquinoline-1 (2H) -ketone derivative | 浙江理工大学嵊州创新研究院有限公司 | 2025-04-15 | — | — | CN | disclosed |
| CN-119816493-A | Multivalent fibroblast activation protein ligand for targeted delivery applications | 菲罗化学股份公司 | 2025-04-11 | — | — | CN | disclosed |
| US-12264156-B2 | Compounds and pharmaceutical compositions thereof for the treatment of diseases | GALAPAGOS NV (BE) | 2025-04-01 | — | — | US | disclosed |
| CN-119698418-A | Heterocyclic compounds, compositions thereof and methods of treatment therewith | 百济神州(苏州)生物科技有限公司 | 2025-03-25 | — | — | CN | disclosed |
| CN-113999249-B | Methods for preparing tricyclic PI3K inhibitor compounds and methods of treating cancer using the same | 基因泰克公司 | 2025-03-25 | — | — | CN | disclosed |
| CN-119633858-A | Near infrared light mediated heterogeneous composite photocatalyst and preparation method and application thereof | 浙江工业大学台州研究院 | 2025-03-18 | — | — | CN | disclosed |
| CN-119638696-A | Methods and compositions for modulating splicing | 斯基霍克疗法公司 | 2025-03-18 | — | — | CN | disclosed |
| EP-4514784-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | Petra Pharma Corporation (US) | 2025-03-05 | — | — | EP | disclosed |
| CN-119528905-A | Methods and compositions for modulating splicing | 斯基霍克疗法公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-119546615-A | Sonrotoclax intermediates and process for their preparation | 百济神州(苏州)生物科技有限公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-119504705-A | Non-peptide somatostatin 5 receptor agonists and uses thereof | 克林提克斯医药股份有限公司 | 2025-02-25 | — | — | CN | disclosed |
| CN-119506909-A | Method for electrochemically synthesizing 3, 4-dihydro-isoquinoline-1 (2H) -ketone compound | 宜宾学院 | 2025-02-25 | — | — | CN | disclosed |
| CN-115872930-B | N-substituted 3, 4-dihydro-isoquinolin-1 (2H) -one derivatives, compositions thereof and use thereof in medicine | 贵州医科大学 | 2025-02-11 | — | — | CN | disclosed |
| US-12221416-B2 | Antagonists of human integrin α4β7 | MORPHIC THERAPEUTIC, INC. (US) | 2025-02-11 | — | — | US | disclosed |
| CN-119384412-A | SARM1 modulators, their preparation and use | 维泰瑞隆有限公司 | 2025-01-28 | — | — | CN | disclosed |
| WO-2025017305-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | REDX PHARMA LIMITED (GB) | 2025-01-23 | — | — | WO | disclosed |
| WO-2025019585-A1 | KINASE INHIBITORS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2025-01-23 | — | — | WO | disclosed |
| CN-119320388-A | Methods and compositions for modulating splicing | 斯基霍克疗法公司 | 2025-01-17 | — | — | CN | disclosed |
| CN-114195764-B | Compound serving as thyroid hormone beta receptor agonist and application thereof | 广东东阳光药业股份有限公司 | 2025-01-17 | — | — | CN | disclosed |
| CN-114269729-B | Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith | 细胞基因公司 | 2025-01-17 | — | — | CN | disclosed |
| CN-119301106-A | Allosteric benzopyrone inhibitors of phosphoinositide 3-kinase (PI 3K) for the treatment of disease | 佩特拉制药公司 | 2025-01-10 | — | — | CN | disclosed |
| CN-119301124-A | Ketal protected intermediates for Sonrotoclax and methods of making the same | 百济神州(苏州)生物科技有限公司 | 2025-01-10 | — | — | CN | disclosed |
| EP-4050006-B1 | BICYCLIC COMPOUND AND USE THEREOF | SK BIOPHARMACEUTICALS CO LTD (KR) | 2025-01-01 | — | — | EP | disclosed |
| EP-4476204-A1 | COMPOUNDS HAVING A T-STRUCTURE FORMED BY AT LEAST FOUR CYCLES FOR USE IN THE TREATMENT OF CANCER AND OTHER INDICATIONS | Theras, Inc. (US) | 2024-12-18 | — | — | EP | disclosed |
| US-20240408081-A1 | NOVEL SYNERGISTIC COMBINATIONS AND METHODS OF USE THEREOF FOR TREATING CANCERS | INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE - INSERM (FR) | 2024-12-12 | — | — | US | disclosed |
| CN-114585614-B | Non-peptide somatostatin 5 receptor agonists and uses thereof | 克林提克斯医药股份有限公司 | 2024-12-03 | — | — | CN | disclosed |
| CN-119013265-A | GLUT9 heterocyclic inhibitors for the treatment of disease | 爱尔兰好利恩治疗有限公司 | 2024-11-22 | — | — | CN | disclosed |
| US-20240383913-A1 | THIOPHENE RING COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SHANGHAITECH UNIVERSITY (CN) | 2024-11-21 | — | — | US | disclosed |
| US-20240376084-A1 | INHIBITORS OF ALPHA-HEMOLYSIN OF STAPHYLOCOCCUS AUREUS | HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH (DE) | 2024-11-14 | — | — | US | disclosed |
| US-20240368173-A1 | TRICYCLIC GPR65 MODULATORS | Pathios Therapeutics Limited (GB) | 2024-11-07 | — | — | US | disclosed |
| CN-118894816-A | 3, 3-Difluoroallylamine or salt thereof and pharmaceutical composition comprising the same | 柳韩洋行 | 2024-11-05 | — | — | CN | disclosed |
| EP-4249481-A4 | DIHYDROISOQUINOLINONE AND ISOINDOLINONE DERIVATIVES AND USES THEREOF | Hefei Institutes of Physical Science, Chinese Academy of Sciences (CN) | 2024-10-30 | — | — | EP | disclosed |
| EP-4448513-A1 | 3, 4-DIHYDROISOQUINOLIN-1 (2H) -ONES DERIVATIVES AS STING ANTAGONISTS AND THE USE THEREOF | BeiGene Switzerland GmbH (CH) | 2024-10-23 | — | — | EP | disclosed |
| EP-4448513-A1 | 3, 4-DIHYDROISOQUINOLIN-1 (2H) -ONES DERIVATIVES AS STING ANTAGONISTS AND THE USE THEREOF | BeiGene Switzerland GmbH (CH) | 2024-10-23 | — | — | EP | disclosed |
| CN-118812532-A | Methods and compositions for modulating splicing | 斯基霍克疗法公司 | 2024-10-22 | — | — | CN | disclosed |
| CN-118791431-A | Dihydro-isoquinolone compounds and isoindoles Selective synthesis method of pinone compound | 常州大学 | 2024-10-18 | — | — | CN | disclosed |
| US-20240343704-A1 | HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2024-10-17 | — | — | US | disclosed |
| CN-118754852-A | Novel dihydroisoquinolinones and application thereof in preparing bactericide for resisting plant pathogenic fungi | 西南交通大学 | 2024-10-11 | — | — | CN | disclosed |
| CN-113453681-B | Substituted 3- ((3-aminophenyl) amino) piperidine-2, 6-dione compounds, compositions thereof, and methods of treatment using the same | 细胞基因公司 | 2024-10-11 | — | — | CN | disclosed |
| CN-118724867-A | Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith | 细胞基因公司 | 2024-10-01 | — | — | CN | disclosed |
| CN-118679163-A | Bicyclic heteroaryl compounds and uses thereof | 上海奕拓医药科技有限责任公司 | 2024-09-20 | — | — | CN | disclosed |
| US-20240299322-A1 | TREATING CANCERS WITH COMBINATIONS OF PARP INHIBITOR AND ACYLFULVENES | LANTERN PHARMA INC. (US) | 2024-09-12 | — | — | US | disclosed |
| US-20240287022-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2024-08-29 | — | — | US | disclosed |
| CN-118556062-A | Compounds, pharmaceutical compositions and methods for treating, preventing or managing hyperproliferative disorders | 文赛克斯制药有限责任公司 | 2024-08-27 | — | — | CN | disclosed |
| CN-118401514-A | 3, 4-Dihydroisoquinolin-1 (2H) -one derivatives as STING antagonists and uses thereof | 百济神州有限公司 | 2024-07-26 | — | — | CN | disclosed |
| CN-118401514-A | 3, 4-Dihydroisoquinolin-1 (2H) -one derivatives as STING antagonists and uses thereof | 百济神州有限公司 | 2024-07-26 | — | — | CN | disclosed |
| CN-118359612-A | Compounds and pharmaceutical compositions for the treatment of diseases | 加拉帕戈斯股份有限公司 | 2024-07-19 | — | — | CN | disclosed |
| CN-118344338-A | Substituted 4-aminoisoindoline-1, 3-dione compounds and their use for the treatment of lymphomas | 细胞基因公司 | 2024-07-16 | — | — | CN | disclosed |
| CN-118284692-A | Gene editing of PCSK9 or ANGPTL3 and compositions and methods of using same for treating diseases | 维乎医疗有限公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-113330001-B | 3, 3-Difluoroallylamine or salt thereof and pharmaceutical composition comprising the same | 柳韩洋行 | 2024-07-02 | — | — | CN | disclosed |
| WO-2024125464-A1 | TETRAHYDROISOQUINOLIN-ONE DERIVATIVES, PREPARATION METHODS AND MEDICINAL USES THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2024-06-20 | — | — | WO | disclosed |
| US-20240182468-A1 | COMPOUNDS FOR THE ACTIVATION OF AMPK | PFIZER (US) | 2024-06-06 | — | — | US | disclosed |
| EP-4376822-A1 | TREATING CANCERS WITH COMBINATIONS OF PARP INHIBITOR AND ACYLFULVENES | Lantern Pharma Inc. (US) | 2024-06-05 | — | — | EP | disclosed |
| CN-114957212-B | Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith | 细胞基因公司 | 2024-05-24 | — | — | CN | disclosed |
| EP-4367123-A1 | PYRIMIDINE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | Glenmark Specialty S.A. (CH) | 2024-05-15 | — | — | EP | disclosed |
| CN-116615417-B | 1, 4-Diheterocyclic group substituted aromatic ring or aromatic heterocyclic compound and application thereof | 广州必贝特医药股份有限公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-115093369-B | Synthesis method of 3, 4-dihydro-isoquinoline-1-ketone compound | 浙大城市学院 | 2024-05-10 | — | — | CN | disclosed |
| CN-118019735-A | Arylsulfonyl compounds as CCR6 inhibitors | 坎莫森特里克斯公司 | 2024-05-10 | — | — | CN | disclosed |
| CN-117946098-A | Pyrimidine PLK1 inhibitor and preparation method and application thereof | 上海深势唯思科技有限责任公司 | 2024-04-30 | — | — | CN | disclosed |
| CN-117946093-A | Compounds useful as HPK1 inhibitors | 深圳福沃药业有限公司 | 2024-04-30 | — | — | CN | disclosed |
| CN-117916368-A | Base editing of thyroxine transporter genes | 比姆医疗股份有限公司 | 2024-04-19 | — | — | CN | disclosed |
| WO-2024006956-A9 | DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-04-11 | — | — | WO | disclosed |
| CN-115260096-B | Method for synthesizing dihydroisoquinolinones based on carbon monoxide gas or carbon monoxide substitution source | 武汉大学 | 2024-04-09 | — | — | CN | disclosed |
| CN-110637015-B | Fanisole X receptor agonist and application thereof | 奥加诺沃公司 | 2024-04-02 | — | — | CN | disclosed |
| CN-114031553-B | Preparation method of 4- [ (methoxyacyl) methyl ] -3, 4-dihydro-isoquinoline-1 (2H) -ketone compound | 郑州师范学院 | 2024-03-22 | — | — | CN | disclosed |
| CN-114031553-B | Preparation method of 4- [ (methoxyacyl) methyl ] -3, 4-dihydro-isoquinoline-1 (2H) -ketone compound | 郑州师范学院 | 2024-03-22 | — | — | CN | disclosed |
| CN-113544186-B | Organic semiconductor composition | 天光材料科技股份有限公司 | 2024-03-19 | — | — | CN | disclosed |
| CN-117730083-A | Pyrimidine compounds as MAP4K1 inhibitors | 格兰马克专业公司 | 2024-03-19 | — | — | CN | disclosed |
| EP-4330246-A1 | HALO-SUBSTITUTED AMINO AZA-HETEROARYL COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | Ontario Institute for Cancer Research (OICR) (CA) | 2024-03-06 | — | — | EP | disclosed |
| CN-111194215-B | Methods and compositions for modulating splicing | 斯基霍克疗法公司 | 2024-03-01 | — | — | CN | disclosed |
| CN-117597340-A | Substituted amino-aza-heteroaryl compounds as inhibitors of hematopoietic progenitor kinase 1 (HPK 1) | 安大略省癌症研究所(OICR) | 2024-02-23 | — | — | CN | disclosed |
| CN-117597336-A | Halogen substituted amino aza-heteroaryl compounds as inhibitors of hematopoietic progenitor kinase 1 (HPK 1) | 安大略省癌症研究所(OICR) | 2024-02-23 | — | — | CN | disclosed |
| CN-115515947-B | SHP2 inhibitor, composition and application thereof | 贝达药业股份有限公司 | 2024-02-06 | — | — | CN | disclosed |
| CN-107915661-B | Organic semiconductor compound | 天光材料科技股份有限公司 | 2024-01-23 | — | — | CN | disclosed |
| WO-2024016014-A2 | METHOD FOR TREATING BREAST CANCERS AND PARP RESISTANT BREAST CANCERS | LANTERN PHARMA INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| CN-117377495-A | Non-peptide targeted therapeutic agent and use thereof | 克林提克斯医药股份有限公司 | 2024-01-09 | — | — | CN | disclosed |
| CN-117377669-A | TYK2 inhibitor and application thereof | 苏多生物科学有限公司 | 2024-01-09 | — | — | CN | disclosed |
| CN-117337289-A | Tetracyclic compounds for the treatment of brain disorders | 加利福尼亚大学董事会 | 2024-01-02 | — | — | CN | disclosed |
| CN-111886233-B | Triazolone derivatives or salts thereof and pharmaceutical compositions containing the same | 柳韩洋行 | 2024-01-02 | — | — | CN | disclosed |
| CN-117242073-A | PRMT5 inhibitors and uses thereof | 海思科医药集团股份有限公司 | 2023-12-15 | — | — | CN | disclosed |
| CN-117242072-A | TYK2 inhibitor and application thereof | 苏多生物科学有限公司 | 2023-12-15 | — | — | CN | disclosed |
| WO-2023240134-A1 | SUBSTITUTED 3,4-DIHYDROISOQUINOLIN-1(2H)-ONE DERIVATIVES AND RELATED USES | NodThera Limited (GB) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023236920-A1 | SARM1 MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2023-12-14 | — | — | WO | disclosed |
| CN-113471251-B | Display assembly, display device and driving method | 华为技术有限公司 | 2023-12-08 | — | — | CN | disclosed |
| CN-108148073-B | Organic semiconductor compound | 天光材料科技股份有限公司 | 2023-12-08 | — | — | CN | disclosed |
| CN-111315796-B | Organic semiconductor compound | 天光材料科技股份有限公司 | 2023-11-24 | — | — | CN | disclosed |
| CN-117120440-A | TYK2 inhibitor and application thereof | 苏多生物科学有限公司 | 2023-11-24 | — | — | CN | disclosed |
| CN-114989085-B | Aryl lactam ring compound, pharmaceutical composition and application thereof | 安徽医科大学 | 2023-11-24 | — | — | CN | disclosed |
| CN-111566089-B | IRE1 small molecule inhibitors | 康奈尔大学 | 2023-11-17 | — | — | CN | disclosed |
| CN-117062816-A | Tricyclic-amide-bicyclic PRMT5 inhibitors | 美国安进公司 | 2023-11-14 | — | — | CN | disclosed |
| WO-2023212693-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PETRA PHARMA CORPORATION (US) | 2023-11-02 | — | — | WO | disclosed |
| CN-116917278-A | Divalent fibroblast activation protein ligands for targeted delivery applications | 菲罗化学股份公司 | 2023-10-20 | — | — | CN | disclosed |
| CN-116888120-A | PRMTS inhibitors | 美国安进公司 | 2023-10-13 | — | — | CN | disclosed |
| EP-4249481-A1 | DIHYDROISOQUINOLINONE AND ISOINDOLINONE DERIVATIVES AND USES THEREOF | Hefei Institutes of Physical Science, Chinese Academy of Sciences (CN) | 2023-09-27 | — | — | EP | disclosed |
| CN-116806218-A | Sulfonamide and its use for the treatment of parasitic helminth infections and diseases | 新基公司 | 2023-09-26 | — | — | CN | disclosed |
| CN-112352328-B | Organic semiconductor compound | 天光材料科技股份有限公司 | 2023-09-22 | — | — | CN | disclosed |
| CN-114262294-B | Phenyl isoquinoline alkaloid compound and preparation method and application thereof | 成都中医药大学 | 2023-09-22 | — | — | CN | disclosed |
| CN-116789726-A | Steroid compound, preparation method and application thereof | 珂阑(上海)医药科技有限公司 | 2023-09-22 | — | — | CN | disclosed |
| CN-116783191-A | Tricyclic carboxamide derivatives as PRMT5 inhibitors | 美国安进公司 | 2023-09-19 | — | — | CN | disclosed |
| CN-116745264-A | Methods and compositions for KRAS modification | 2692372安大略公司 | 2023-09-12 | — | — | CN | disclosed |
| CN-110998888-B | organic semiconducting polymers | 天光材料科技股份有限公司 | 2023-09-12 | — | — | CN | disclosed |
| CN-116744918-A | HSD17B13 inhibitors and uses thereof | FL2022-001公司 | 2023-09-12 | — | — | CN | disclosed |
| CN-111094253-B | 1, 2-dihydro-3H-pyrazolo [3,4-d ] pyrimidin-3-one analogs | 里科瑞尔姆IP控股有限责任公司 | 2023-08-29 | — | — | CN | disclosed |
| WO-2023154282-A1 | COMPOUNDS HAVING A T-STRUCTURE FORMED BY AT LEAST FOUR CYCLES FOR USE IN THE TREATMENT OF CANCER AND OTHER INDICATIONS | THERAS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| CN-116600801-A | HSD17B13 inhibitors and uses thereof | FL2022-001公司 | 2023-08-15 | — | — | CN | disclosed |
| CN-116583303-A | Tripterine conjugates and uses thereof | 瑞阳公司 | 2023-08-11 | — | — | CN | disclosed |
| CN-116547282-A | Heterocyclic compounds and their use for the treatment of helminth infections and diseases | 新基公司 | 2023-08-04 | — | — | CN | disclosed |
| WO-2023143393-A1 | TRICYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海科技大学 | 2023-08-03 | — | — | WO | disclosed |
| CN-116514824-A | Tri-ring compound, preparation method and application thereof | 上海科技大学 | 2023-08-01 | — | — | CN | disclosed |
| CN-111698989-B | Heterocyclic substituted pyridine derivatives as antifungal agents | 安普利克斯制药公司 | 2023-08-01 | — | — | CN | disclosed |
| CN-116507608-A | Compounds, compositions, and methods | 戴纳立制药公司 | 2023-07-28 | — | — | CN | disclosed |
| CN-116438174-A | Compounds and their use as MIF inhibitors | 南京艾美斐生物医药科技有限公司 | 2023-07-14 | — | — | CN | disclosed |
| CN-116438180-A | Tricyclic neural plasticizers and uses thereof | 德力克斯疗法有限公司 | 2023-07-14 | — | — | CN | disclosed |
| CN-112236882-B | Organic semiconductor compound | 天光材料科技股份有限公司 | 2023-06-30 | — | — | CN | disclosed |
| WO-2023121238-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING SAME | (주)메디픽 | 2023-06-29 | — | — | WO | disclosed |
| WO-2023109912-A1 | 3, 4-DIHYDROISOQUINOLIN-1 (2H) -ONES DERIVATIVES AS STING ANTAGONISTS AND THE USE THEREOF | BEIGENE, LTD. (KY) | 2023-06-22 | — | — | WO | disclosed |
| CN-110177783-B | Hormone receptor modulators for the treatment of metabolic conditions and disorders | 阿德利克斯股份有限公司 | 2023-06-06 | — | — | CN | disclosed |
| CN-116157398-A | 2- (4- ((5- (benzo [ b ] thiophen-3-yl) -1H-tetrazol-1-yl) methyl) phenyl) -5- (difluoromethyl) -1,3, 4-oxadiazole derivatives and similar compounds as selective inhibitors of histone deacetylase 6 (HDAC 6) for the treatment of, for example, peripheral neuropathy | 意大发马克股份公司 | 2023-05-23 | — | — | CN | disclosed |
| CN-116096429-A | Base editing of PCSK9 and methods of use thereof for treating diseases | 维乎医疗有限公司 | 2023-05-09 | — | — | CN | disclosed |
| CN-116096883-A | Base editing of ANGPTL3 and methods of treating diseases using the same | 维乎医疗有限公司 | 2023-05-09 | — | — | CN | disclosed |
| US-11638706-B2 | Methods for treating Huntington's disease | PTC THERAPEUTICS, INC. (US) | 2023-05-02 | — | — | US | disclosed |
| EP-4168399-A1 | COMPOUNDS AND THEIR USES AS MIF INHIBITORS | Nanjing Immunophage Biotech Co., Ltd. (CN) | 2023-04-26 | — | — | EP | disclosed |
| CN-115968293-A | Cereblon binding compounds, compositions thereof, and methods of use thereof for treatment | 新基公司 | 2023-04-14 | — | — | CN | disclosed |
| CN-115955979-A | Cereblan binding compounds, compositions thereof, and methods for treatment thereof | 新基公司 | 2023-04-11 | — | — | CN | disclosed |
| CN-115872930-A | N-substituted 3,4-dihydroisoquinoline-1 (2H) -ketone derivative, composition thereof and application thereof in medicines | 贵州医科大学 | 2023-03-31 | — | — | CN | disclosed |
| CN-111825656-B | Inhibitors of protein arginine methyltransferase 5 (PRMT 5), pharmaceutical products thereof, and methods thereof | 南京药石科技股份有限公司 | 2023-03-31 | — | — | CN | disclosed |
| EP-4151208-A1 | NOVEL SYNERGISTIC COMBINATIONS AND METHODS OF USES THEREOF FOR TREATING CANCERS | UNIVERSITE DE BORDEAUX (FR) | 2023-03-22 | — | — | EP | disclosed |
| CN-115835866-A | Cereblon binding compounds, compositions thereof, and methods of use thereof for treatment | 新基公司 | 2023-03-21 | — | — | CN | disclosed |
| US-11608501-B2 | Methods for modifying RNA splicing | PTC THERAPEUTICS, INC. (US) | 2023-03-21 | — | — | US | disclosed |
| WO-2023010119-A1 | TREATING CANCERS WITH COMBINATIONS OF PARP INHIBITOR AND ACYLFULVENES | LANTERN PHARMA INC. (US) | 2023-02-02 | — | — | WO | disclosed |
| CN-110294742-B | Fused ring ASK1 inhibitor and application thereof | 山东轩竹医药科技有限公司 | 2023-01-31 | — | — | CN | disclosed |
| US-20230026466-A1 | WDR5 INHIBITORS AND MODULATORS | VANDERBILT UNIVERSITY | 2023-01-26 | — | — | US | disclosed |
| US-20230023140-A1 | BICYCLIC COMPOUND AND USE THEREOF | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2023-01-26 | — | — | US | disclosed |
| US-20230017532-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-19 | — | — | US | disclosed |
| WO-2023281417-A1 | PYRIMIDINE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | GLENMARK SPECIALTY S.A. (CH) | 2023-01-12 | — | — | WO | disclosed |
| CN-115515947-A | SHP2 inhibitor and composition and application thereof | 贝达药业股份有限公司 | 2022-12-23 | — | — | CN | disclosed |
| US-20220402911-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | GALAPAGOS NV (BE) | 2022-12-22 | — | — | US | disclosed |
| CN-115397412-A | Modulators of MAS-related G protein receptor X4 and related products and methods | 伊赛恩特制药公司 | 2022-11-25 | — | — | CN | disclosed |
| CN-115286557-A | Preparation method of 3-alkenyl isoindoline-1-ketone derivative and prepared derivative | 宿州学院 | 2022-11-04 | — | — | CN | disclosed |
| WO-2022226665-A1 | HALO-SUBSTITUTED AMINO AZA-HETEROARYL COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2022-11-03 | — | — | WO | disclosed |
| WO-2022226668-A1 | HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2022-11-03 | — | — | WO | disclosed |
| EP-4076459-A1 | PRMT5 INHIBITORS | Merck Sharp & Dohme LLC (US) | 2022-10-26 | — | — | EP | disclosed |
| WO-2022206964-A1 | PRMT5 INHIBITOR AND USE THEREOF | 海思科医药集团股份有限公司 | 2022-10-06 | — | — | WO | disclosed |
| CN-115093369-A | Synthetic method of 3, 4-dihydroisoquinoline-1-ketone compound | 浙大城市学院 | 2022-09-23 | — | — | CN | disclosed |
| US-20220289732-A1 | HETEROCYCLIC WDR5 INHIBITORS AS ANTI-CANCER COMPOUNDS | NOVARTIS AG (CH) | 2022-09-15 | — | — | US | disclosed |
| EP-4055013-A1 | WDR5 INHIBITORS AND MODULATORS | Vanderbilt University (US) | 2022-09-14 | — | — | EP | disclosed |
| CN-115052627-A | IRAK degrading agents and uses thereof | 凯麦拉医疗公司 | 2022-09-13 | — | — | CN | disclosed |
| CN-114989085-A | Aryl lactam ring compound, pharmaceutical composition and application thereof | 安徽医科大学 | 2022-09-02 | — | — | CN | disclosed |
| CN-114957212-A | Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith | 细胞基因公司 | 2022-08-30 | — | — | CN | disclosed |
| CN-114945562-A | Bicyclic compounds and uses thereof | 爱思开生物制药株式会社 | 2022-08-26 | — | — | CN | disclosed |
| WO-2022173849-A1 | (HETERO)ARYLAMINO-CYCLOHEXYL-SULFONYL DERIVATIVES AS CCR6 INHIBITORS | QILU REGOR THERAPEUTICS INC. (CN) | 2022-08-18 | — | — | WO | disclosed |
| CN-114829344-A | Novel pyrimidine derivative and use thereof | 韩国化学研究院 | 2022-07-29 | — | — | CN | disclosed |
| CN-114698370-A | Compounds and methods for treating cytokine release syndrome | 里格尔药品股份有限公司 | 2022-07-01 | — | — | CN | disclosed |
| EP-4010334-A1 | HETEROCYCLIC WDR5 INHIBITORS AS ANTI-CANCER COMPOUNDS | Novartis AG (CH) | 2022-06-15 | — | — | EP | disclosed |
| CN-109069512-B | Substituted aminopurine compounds, compositions thereof, and related methods of treatment | 西格诺药品有限公司 | 2022-06-14 | — | — | CN | disclosed |
| CN-109476696-B | Anti-trypanosome and anti-leishmania agents for animals and humans | 细胞基因公司 | 2022-06-10 | — | — | CN | disclosed |
| CN-114516856-A | Dihydroisoquinolinone and isoindolinone derivatives and uses thereof | 中国科学院合肥物质科学研究院 | 2022-05-20 | — | — | CN | disclosed |
| CN-114262294-A | Phenylisoquinoline alkaloid compound and preparation method and application thereof | 成都中医药大学 | 2022-04-01 | — | — | CN | disclosed |
| CN-114269729-A | Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith | 细胞基因公司 | 2022-04-01 | — | — | CN | disclosed |
| CN-109563094-B | (hetero) aryl-substituted piperidinyl derivatives, process for their preparation and pharmaceutical compositions containing them | 法国施维雅药厂 | 2022-03-18 | — | — | CN | disclosed |
| CN-114195764-A | Compound as thyroid hormone beta receptor agonist and application thereof | 广东东阳光药业有限公司 | 2022-03-18 | — | — | CN | disclosed |
| US-20220081422-A1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | JANSSEN BIOTECH, INC. | 2022-03-17 | — | — | US | disclosed |
| CN-114007611-A | Methods and compositions for modulating splicing | 斯基霍克疗法公司 | 2022-02-01 | — | — | CN | disclosed |
| CN-114007611-A | Methods and compositions for modulating splicing | 斯基霍克疗法公司 | 2022-02-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (24 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132132-A1 | 3A,4,5,6-TETRAHYDRO-1 H-PYRAZOLO[3,4-C]PYRIDIN-7(7AH)-ONE DERIVATIVES AS FACTOR XIIA INHIBITORS | F11, F13B, F7 | PARP10 1988/4885PARP1 462/4885PARP11 294/4885 |
| US-20250161247-A1 | METHOD FOR TREATING BREAST CANCERS AND PARP RESISTANT BREAST CANCERS | PARP1, PARP2, PARP3 | PARP10 14/4885PARP1 1/4885PARP11 4/4885 |
| US-20240182468-A1 | COMPOUNDS FOR THE ACTIVATION OF AMPK | PRKAG1, PRKAG2, PRKAB1 | PARP10 620/4885PARP1 512/4885PARP11 470/4885 |
| US-20250320184-A1 | SARM1 MODULATORS, PREPARATIONS, AND USES THEREOF | SARM1, SMN1; SMN2, ADRM1 | PARP10 697/4885PARP1 943/4885PARP11 428/4885 |
| US-20240368173-A1 | TRICYCLIC GPR65 MODULATORS | GPR65, GPR3, NR1H2 | PARP10 970/4885PARP1 4106/4885PARP11 2055/4885 |
| US-20220081422-A1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | DHODH, DLD, DPYD | PARP10 806/4885PARP1 1458/4885PARP11 997/4885 |
| US-12391674-B2 | Heterocyclic compounds for the treatment of epilepsy | SLC6A11, SCN1A, SCN1B | PARP10 4400/4885PARP1 4570/4885PARP11 3742/4885 |
| US-20240299322-A1 | TREATING CANCERS WITH COMBINATIONS OF PARP INHIBITOR AND ACYLFULVENES | PARP1, PARP2, PARP11 | PARP10 8/4885PARP1 1/4885PARP11 3/4885 |
| US-20230023140-A1 | BICYCLIC COMPOUND AND USE THEREOF | PRMT5, PRMT6, PRMT1 | PARP10 58/4885PARP1 205/4885PARP11 63/4885 |
| US-20220402911-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | IL1A, TNF, IL6 | PARP10 2139/4885PARP1 2937/4885PARP11 2707/4885 |
| US-12221416-B2 | Antagonists of human integrin α4β7 | ITGB7, ITGB4, ITGA4 | PARP10 1124/4885PARP1 2259/4885PARP11 1851/4885 |
| US-20230026466-A1 | WDR5 INHIBITORS AND MODULATORS | WDR5, WDR1, WDR3 | PARP10 482/4885PARP1 1578/4885PARP11 510/4885 |
| US-12264156-B2 | Compounds and pharmaceutical compositions thereof for the treatment of diseases | TNF, IL1A, COL1A1 | PARP10 2425/4885PARP1 2964/4885PARP11 2799/4885 |
| US-12637461-B2 | Compounds for the activation of AMPK | PRKAG1, PRKAB1, PRKAA1 | PARP10 546/4885PARP1 537/4885PARP11 308/4885 |
| US-12331035-B2 | Bicyclic compound and use thereof | PRMT5, PRMT6, PRMT1 | PARP10 58/4885PARP1 205/4885PARP11 63/4885 |
| US-20250178999-A1 | ONE STEP SYNTHESIS OF 1-TETRALONE COMPOUNDS AND USES THEREOF IN THE PREPARATION OF (+)-TETRALONE ABSCISIC ACID (ABA) | AAK1, ACSL1, COASY | PARP10 4521/4885PARP1 3829/4885PARP11 3356/4885 |
| US-20220289732-A1 | HETEROCYCLIC WDR5 INHIBITORS AS ANTI-CANCER COMPOUNDS | WDR5, WDR77, WDR1 | PARP10 512/4885PARP1 1292/4885PARP11 326/4885 |
| US-20240376084-A1 | INHIBITORS OF ALPHA-HEMOLYSIN OF STAPHYLOCOCCUS AUREUS | SERPINB1, LTA, SERPINC1 | PARP10 3970/4885PARP1 4191/4885PARP11 3593/4885 |
| US-20240383913-A1 | THIOPHENE RING COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | TACR1, HTR1F, TPH1 | PARP10 3218/4885PARP1 4178/4885PARP11 2465/4885 |
| US-20230017532-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, O60361, MYD88 | PARP10 3083/4885PARP1 2724/4885PARP11 1435/4885 |
| US-11608501-B2 | Methods for modifying RNA splicing | RBM17, SNRPA1, SNRPE | PARP10 1660/4885PARP1 3428/4885PARP11 1952/4885 |
| US-20240287022-A1 | IL4I1 INHIBITORS AND METHODS OF USE | IL4I1, IL4, IL1RN | PARP10 3657/4885PARP1 4531/4885PARP11 3233/4885 |
| US-20240343704-A1 | HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | CMPK1, WNK1, AAK1 | PARP10 2072/4885PARP1 2516/4885PARP11 1176/4885 |
| US-11638706-B2 | Methods for treating Huntington's disease | HTT, HYPK, FH | PARP10 3382/4885PARP1 3055/4885PARP11 2887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.